4.6 Article

Fatty acids in the de novo lipogenesis pathway and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies

Journal

PLOS MEDICINE
Volume 17, Issue 6, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pmed.1003102

Keywords

-

Funding

  1. United Kingdom Medical Research Council Epidemiology Unit core grant [MC_UU_12015/5, MC_UU_12015/1]
  2. National Institute for Health Research (NIHR) Biomedical Research Centre Cambridge [IS-BRC-1215-20014]
  3. Dutch Scientific Organization (ZonMW)
  4. Foundation Plan Alzheimer
  5. NIH [3T32DK007703, T32CA009001, UM1 CA167552, R01 HL35464, AA11181, HL35464, CA55075, HL60712, P30 DK46200, M01-RR-43, CA186107, CA87969, CA49449, HL34594, CA167552, HL088521]
  6. Netherlands Heart Foundation [2000T401]
  7. NIH (NIH/National Heart, Lung, and Blood Institute [NHLBI])
  8. NIH (ODS) [R01HL-076200]
  9. Unilever RD, Vlaardingen
  10. United States National Institute of Health (NIH) [N01-AG012100]
  11. National Institute of Aging (NIA) Intramural Research Program
  12. Hjartavernd (the Icelandic Heart Association)
  13. Althingi (the Icelandic Parliament)
  14. Michael Smith Foundation for Medical Research [17644]
  15. Canadian Cancer Society [704735]
  16. Ministry of Science and Technology
  17. National Taiwan University, Taiwan [MOST 103-2314-B-002 -135-MY3, NSC 100-2314-B-002 -113 -MY3, NTUH 105-S3120, NTUH 106-S3453]
  18. National Institute of Neurological Disorders and Stroke (NINDS)
  19. NIA [R01AG023629]
  20. NHLBI
  21. Boston University [N01-HC25195]
  22. EU FP6 programme [LSHM_CT_2006_037197]
  23. Academy of Finland
  24. VicHealth
  25. Cancer Council Victoria
  26. Australia's National Health and Medical Research Council [209057, 126403]
  27. NCRR [UL1-TR000040, UL1-TR-001079]
  28. European Union
  29. Juselius Foundation
  30. Uppsala University Hospital
  31. Swedish Research Council for Health, Working Life and Welfare
  32. Agence Nationale de la Recherche [COGINUT ANR-06-PNRA-005]
  33. Fondation Plan Alzheimer [FCS 2009-2012]
  34. Uppsala City Council
  35. Swedish Research Council
  36. Swedish Diabetes Foundation (UR)
  37. NHLBI, NIH, U.S. Department of Health and Human Services [HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, HHSN268201600004C]
  38. Fondation pour la Recherche Medicale
  39. Caisse Nationale Maladie des Travailleurs Salaries
  40. Direction Generale de la Sante
  41. MGEN
  42. Institut de la Longevite
  43. Conseils Regionaux d'Aquitaine et Bourgogne
  44. Fondation de France
  45. Ministry of Research-Institut National de la Sante
  46. Caisse Nationale pour la Solidarite et l'Autonomie
  47. NHLBI [HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, R01-HL-085710, U01HL080295, U01HL130114, U01-HL-47892, U01-HL-47902, N01-HC-95161, N01-HC-95162, N01-HC95163, N01-HC-95164, N01-HC-95165, N01-HC95166, N01-HC-95167, N01-HC-95168, N01HC-95169]
  48. [DK-29867]
  49. [R01-58329]
  50. [DK-079888]
  51. [HHSN268201500003I]
  52. [N01-HC-95159]
  53. [N01-HC95160]
  54. MRC [MC_UU_12015/5, MC_UU_00006/3, MC_UU_12015/1, MC_UU_00014/5] Funding Source: UKRI

Ask authors/readers for more resources

Background De novo lipogenesis (DNL) is the primary metabolic pathway synthesizing fatty acids from carbohydrates, protein, or alcohol. Our aim was to examine associations of in vivo levels of selected fatty acids (16:0, 16:1n7, 18:0, 18:1n9) in DNL with incidence of type 2 diabetes (T2D). Methods and findings Seventeen cohorts from 12 countries (7 from Europe, 7 from the United States, 1 from Australia, 1 from Taiwan; baseline years = 1970-1973 to 2006-2010) conducted harmonized individual-level analyses of associations of DNL-related fatty acids with incident T2D. In total, we evaluated 65,225 participants (mean ages = 52.3-75.5 years; % women = 20.4%62.3% in 12 cohorts recruiting both sexes) and 15,383 incident cases of T2D over the 9-year follow-up on average. Cohort-specific association of each of 16:0, 16:1n7, 18:0, and 18:1n9 with incident T2D was estimated, adjusted for demographic factors, socioeconomic characteristics, alcohol, smoking, physical activity, dyslipidemia, hypertension, menopausal status, and adiposity. Cohort-specific associations were meta-analyzed with an inverse-varianceweighted approach. Each of the 4 fatty acids positively related to incident T2D. Relative risks (RRs) per cohort-specific range between midpoints of the top and bottom quintiles of fatty acid concentrations were 1.53 (1.41-1.66; p< 0.001) for 16:0, 1.40 (1.33-1.48; p< 0.001) for 16:1n-7, 1.14 (1.05-1.22; p = 0.001) for 18:0, and 1.16 (1.07-1.25; p< 0.001) for 18:1n9. Heterogeneity was seen across cohorts (I-2 = 51.1%-73.1% for each fatty acid) but not explained by lipid fractions and global geographical regions. Further adjusted for triglycerides (and 16:0 when appropriate) to evaluate associations independent of overall DNL, the associations remained significant for 16:0, 16:1n7, and 18:0 but were attenuated for 18:1n9 (RR = 1.03, 95% confidence interval (CI) = 0.94-1.13). These findings had limitations in potential reverse causation and residual confounding by imprecisely measured or unmeasured factors. Conclusions Concentrations of fatty acids in the DNL were positively associated with T2D incidence. Our findings support further work to investigate a possible role of DNL and individual fatty acids in the development of T2D.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available